ArticleBMC health services research2024

Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma.

Pingyu Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.